Pacific Edge Limited · NZX:PEB
Pacific Edge — Shareholder Meeting (August 2020)
33 slides from Pacific Edge's shareholder meeting presentation, Aug 5, 2020
Slide 1: Pacific Edge Annual Meeting
PACIFIC EDGE ANNUAL MEETING 5 August 2020
Slide 2: Board of Directors
BOARD OF DIRECTORS GOVERNANCE Board of Directors Experience in governance, finance, sales management, cancer research, biotechnology and life sciences, investment and business advisory. Chris Gallaher Bryan Williams Anatole Masfen Subsidiary Board Directors In-country commercial experience and scien
Slide 3: Meeting Agenda
MEETING AGENDA • Presentations: • Address from the Chair, Chris Gallaher • Address from the Chief Executive Officer, Dave Darling • Shareholder Discussion • Resolutions as per Notice of Meeting: • Re-election of Bryan Williams and Dave Darling • Authorise the Directors to fix the auditor’s remunerat
Slide 4: Chairman's Address
CHAIRMAN’S ADDRESS Chris Gallaher 4
Slide 5: Milestones on Our Commercial Journey
MILESTONES ON OUR COMMERCIAL JOURNEY • Evolution of Pacific Edge from a research organisation to a commercial entity. • Development of commercial strategy for New Zealand, Australia and USA, world’s largest healthcare market. • Development and launch of world class CLIA and CAP accredited laboratori
Slide 6: Responding to COVID-19
RESPONDING TO COVID-19 • Operated as an essential business during COVID-19 restrictions in NZ and the USA. • Reduction in Total Laboratory Throughput during April 2020. Recovery from May 2020 following the easing of restrictions and growing demand for our in-home sample collection service. • Took st
Slide 7: We Are Poised to Grow
WE ARE POISED TO GROW Launch and commercialise all four Cxbladder products in our targeted markets around the world to drive a profitable business. Pil OUR Sustain the global first mover advantage with Cxbladder GROWTH STRATEGY becoming the preferred go-to Attain global reach with detection and mana
Slide 8: We Have a Strong Outlook
WE HAVE A STRONG OUTLOOK • Test use and revenue expected to ramp up in FY21. “We are now on the cusp of realising our full commercial • Cash and cashflow management remain front of mind; escalation of commercial test sales expected to have a potential. Our company is uniquely positive impact on our
Slide 9: Chief Executive Officer's Address
CHIEF EXECUTIVE OFFICER’S ADDRESS Dave Darling 9
Slide 10: Progress Against Strategic Goals
PROGRESS AGAINST STRATEGIC GOALS 10
Slide 11: Launch and Commercialise All Four Cxbladder Products
LAUNCH AND COMMERCIALISE ALL FOUR CXBLADDER PRODUCTS IN OUR TARGETED MARKETS AROUND THE WORLD TO DRIVE A PROFITABLE BUSINESS. Cxbladder in a class of its own; • Suite of four, class leading, accurate, non-invasive, urine based diagnostic tests for urothelial cancer (UC). • Addressing multiple unmet
Slide 12: Sustain the Global First Mover Advantage with Cxbladder
SUSTAIN THE GLOBAL FIRST MOVER ADVANTAGE WITH CXBLADDER BECOMING THE PREFERRED GO-TO DETECTION AND MANAGEMENT TESTS FOR UROTHELIAL CANCER. • Increasing validation by international urologists and in per reviewed published literature. • Inclusion in clinical guidelines in New Zealand and USA’s NCCN gu
Slide 13: Growing Portfolio of Peer Reviewed, Published Papers
GROWING PORTFOLIO OF PEER REVIEWED, PUBLISHED PAPERS • Publication of peer-reviewed papers is key to gaining adoption, recognition in guidelines and positive reimbursement decisions for coverage. • Generated in excess of 10 years of accumulated evidence and multiple, major peer reviewed publications
Slide 14: Inclusion in Clinical Guidelines
INCLUSION IN CLINICAL GUIDELINES Inclusion in guidelines follows significant adoption, and further empowers urologists and organisations to adopt and use our products. • Majority of New Zealand’s public healthcare providers have adopted Cxbladder into their standard of care, and in some cases, into
Slide 15: Inclusion in LCD Fully Enables CMS Reimbursement
INCLUSION IN LCD FULLY ENABLES CMS REIMBURSEMENT USA Reimbursement Milestones Achieved: Successful inclusion in the LCD is expected to result in significant commercial growth: ✓ Receipt of Product Specific CPT codes for Cxbladder Detect and Cxbladder • Enables reimbursement by CMS* for all Monitor (
Slide 16: Grow Adoption by Large Scale Institutional Healthcare Customers
GROW THE ADOPTION OF CXBLADDER BY LARGE SCALE INSTITUTIONAL HEALTHCARE CUSTOMERS, FOR MULTIPLE TARGETED CLINICAL NEEDS • Building on success achieved with large public healthcare providers in New Zealand and most recently, Kaiser Permanente in the USA to conclude commercial agreements with other sca
Slide 17: Commercial Agreement Reached with Kaiser Permanente
COMMERCIAL AGREEMENT REACHED WITH KAISER PERMANENTE “Cxbladder’s ability to provide for the collection of the urine sample in-home will allow Kaiser Permanente patients to be regularly tested for bladder cancer at home and will also enable their physicians to do more patient management using tele- c
Slide 18: Growing Evaluation and Use by Large Healthcare Institutions
GROWING EVALUATION AND USE OF CXBLADDER BY LARGE HEALTHCARE INSTITUTIONS USA USA SOUTH EAST ASIA • Kaiser Permanente • University of California-San • Singapore General Hospital • Carolina Urologic Research Diego • Tan Tock Seng Center • University of California-San • Khoo Tech Puat Hospital • City o
Slide 19: Adapting to COVID-19: Telehealth
ADAPTING TO COVID-19: TELEHEALTH • COVID-19 pandemic has catalysed a dramatic increase in the use of telehealth as the primary mode of consultation for patients1. • Cxbladder is now being used to enable tele-health. The Cxbladder in-home urine sample collection process incorporates the delivery of C
Slide 20: Dr Nancy Gin, Kaiser Permanente, July 2020
Dr Nancy Gin, Chief of Clinical Quality at Kaiser Permanente: July 2020 “… we have seen dramatic shifts in telemedicine in just the past few months. At Kaiser Permanente healthcare visits delivered remotely have increased from about one in five visits before the pandemic to more than four in five to
Slide 21: FY20 Performance
» —!~ PACIFIC EDGE Cancer Diagnostic Company FY20 PERFORMANCE
Slide 22: FY20 Financial Summary
FY20 FINANCIAL SUMMARY $Millions FY20 FY19 % change ✓ Increase in Operating Revenue Operating Revenue1 4.4 3.8 14% ✓ Increase in cash receipts from customers Total Revenue 5.2 5.1 1% ✓ Improvement in Net Operating Cashflow Operating Expenses 24.1 23.0 (5)% 2 ✓ Small increase in Operating Expenses –
Slide 23: Near Term Goals and Catalysts for Growth
NEAR TERM GOALS AND CATALYSTS FOR GROWTH 23
Slide 24: Catalysts to Drive Growth Through FY21: USA
CATALYSTS TO DRIVE GROWTH THROUGH FY21: USA Primary focus for all markets is achieving commercial contracts with large institutional healthcare customers and growing sales to existing customers • Leverage the recent inclusion in the LCD to gain coverage with private insurers. • Ramp up in demand fro
Slide 25: Rest of World: Near Term Goals
REST OF WORLD NEAR TERM GOALS: CATALYSTS TO DRIVE GROWTH NEW ZEALAND • Further adoption of Cxbladder • Bring the NZ business to a cash-flow positive position. by public healthcare providers in NZ and Australia. • Extend the commercial coverage by public healthcare providers in NZ from 65% toward 100
Slide 26: Near Term Actions and Outlook
NEAR TERM ACTIONS AND OUTLOOK • Near term objective is to grow revenue and improve cashflow. • Primary focus is on executing on two recent commercial catalysts – the LCD for CMS patients and reaching a commercial agreement with Kaiser Permanente. • LCD: • In FY20 we processed 4,691 (43%) commercial
Slide 27: Shareholder Discussion
» —!~ PACIFIC EDGE Cancer Diagnostic Company SHAREHOLDER DISCUSSION
Slide 28: Business of the Meeting
» —!~ PACIFIC EDGE Cancer Diagnostic Company BUSINESS OF THE MEETING
Slide 29: Resolutions
RESOLUTIONS • Resolution 1: That Bryan Williams, who retires by rotation and is eligible for re-election, be re-elected as a Director of the Company. • Resolution 2: That Dave Darling, who retires by rotation and is eligible for re-election, be re-elected as a Director of the Company. • Resolution 3
Slide 30: Proxies and Voting
PROXIES AND VOTING We have received the following valid votes and proxies: PROXIES AND POSTAL VOTES FOR AGAINST DISCRETIONARY VALID % OF TOTAL VOTES/PROXIES ISSUED CAPITAL RECEIVED 1 Re-election of Bryan Williams 265,069,764 5,085,559 8,838,728 278,539,051 38.46% 95.16% 1.83% 3.01% 2 Re-election of
Slide 31: Other Business
» —!~ PACIFIC EDGE Cancer Diagnostic Company OTHER BUSINESS
Slide 32: Close of the Meeting
Close of the Meeting Presentations are available at www.pacificedgedx.com www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com
Slide 33: Disclaimer
DISCLAIMER Information The information in this presentation is an overview and does not contain all information necessary to make an investment decision. It is intended to constitute a summary of certain information relating to the performance of Pacific Edge Limited. The information in this present